HH-185 is under clinical development by 3D Medicines and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HH-185’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HH-185 is under development for the treatment of solid tumors and pulmonary fibrosis, ulcerative colitis and advanced/metastatic cholangiocarcinoma. The drug candidate acts by targeting fibroblast growth factor receptors 1, 2, 3 (FGFR1, 2, 3). It is administered through oral route.
3D Medicines overview
3D Medicines is a precision medicine company which provides cancer precision medical treatment. The company provides ANDiS SARS-CoV-2 detection kit and the ANDiS SARS-CoV-2 and influenza A/B detection kit. The company offers cancer diagnosis and treatment through the integration of biological characteristics, clinical diagnosis and treatment, and drug research and development data mining application. It offers precision cancer prevention, precision cancer diagnosis, and precision drug development. 3D Medicines offers services for different people, which covers tumor tissue and blood samples. The company also operates in the field of drug development that covers immunotherapy and other biomarker-Driven targeting therapy. It has operations in China, Japan and the US. 3D Medicines is headquartered in Shanghai, China.
For a complete picture of HH-185’s drug-specific PTSR and LoA scores, buy the report here.